Chronic hepatitis D and hepatocellular carcinoma: A systematic review and meta-analysis of observational studies
- PMID: 32151618
- DOI: 10.1016/j.jhep.2020.02.030
Chronic hepatitis D and hepatocellular carcinoma: A systematic review and meta-analysis of observational studies
Abstract
Background & aims: Chronic hepatitis D (CHD) is the most severe form of chronic viral hepatitis but its role in the development of hepatocellular carcinoma (HCC) remains debated. We conducted a systematic review and meta-analysis of epidemiological studies to examine whether CHD is associated with an increased risk of HCC.
Methods: We searched PubMed, Embase and Web of Science, as well as study references and conference proceedings. We considered cohort and case-control studies allowing the calculation of effect estimates for the association between CHD (exposure) and HCC (outcome) in comparison to chronic hepatitis B. Data extraction and quality evaluation (using the Newcastle-Ottawa scale) were performed independently by 2 authors. Data were pooled using random-effects models.
Results: Ninety-three studies (68 case-control studies including 22,862 patients and 25 cohort studies including 75,427 patients) were included. Twelve studies accounted for confounders, in either study design or analysis (10 of which were cohorts), and 11 cohorts were prospective. The overall analysis showed a significantly increased risk of HCC in patients with CHD, despite substantial study heterogeneity (pooled odds ratio 1.28; 95% CI 1.05-1.57; I2 = 67.0%). The association was particularly strong in the absence of heterogeneity for prospective cohort studies (pooled odds ratio 2.77; 95% CI 1.79-4.28; I2 = 0%), and studies with HIV-infected patients (pooled odds ratio 7.13; 95% CI 2.83-17.92; I2 = 0%).
Conclusions: We found a significantly higher risk of HCC in patients with CHD. Although further studies are needed to definitively exclude a potential bias due to antiviral treatments, our findings highlight the rationale for improved screening of hepatitis D virus infection in patients with chronic hepatitis B, and the urgent need for novel and effective antiviral therapies.
Lay summary: Hepatitis D virus (HDV) is a defective pathogen requiring hepatitis B virus (HBV) to complete its life cycle. Chronic hepatitis D is the most severe form of chronic viral hepatitis, increasing the risk of cirrhosis, liver decompensation and death compared to HBV monoinfection. However, the association between HDV infection and increased risk of hepatocellular carcinoma is debated. We conducted a systematic review and found that patients with HDV infection had a significantly higher risk of developing hepatocellular carcinoma than those with HBV monoinfection.
Keywords: Antivirals; Coinfection; HCC; Hepatitis B virus; Hepatitis D virus.
Copyright © 2020 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.
Conflict of interest statement
Conflict of interest The authors declare no conflicts of interest that pertain to this work. Please refer to the accompanying ICMJE disclosure forms for further details.
Comment in
-
The burden of hepatitis D - defogging the epidemiological horizon.J Hepatol. 2020 Sep;73(3):493-495. doi: 10.1016/j.jhep.2020.06.037. Epub 2020 Jul 16. J Hepatol. 2020. PMID: 32684365 No abstract available.
-
Reply to: "Cirrhotic controls in a pooled analysis of hepatitis D and hepatocellular carcinoma".J Hepatol. 2020 Dec;73(6):1585-1586. doi: 10.1016/j.jhep.2020.08.012. Epub 2020 Sep 12. J Hepatol. 2020. PMID: 32933779 No abstract available.
-
Cirrhotic controls in a pooled analysis of hepatitis D and hepatocellular carcinoma.J Hepatol. 2020 Dec;73(6):1583-1584. doi: 10.1016/j.jhep.2020.07.012. Epub 2020 Sep 19. J Hepatol. 2020. PMID: 32962868 Free PMC article. No abstract available.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
